Initiator Pharma A/S (STO:INIT)

Market Cap	123.90M -36.7%
Revenue (ttm)	n/a
Net Income	-41.77M
EPS	-0.61
Shares Out	68.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	96,523
Open	1.915
Previous Close	1.945
Day's Range	1.810 - 1.915
52-Week Range	1.665 - 3.650
Beta	0.14
Analysts	n/a
Price Target	5.52 (+204.97%)
Earnings Date	Nov 20, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical-stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous systems. The company is developing Pudafensine, a monoamine reuptake inhibitor that has completed a Phase IIb clinical trial primarily targeting the dopamine system for the treatment of treatment-resistant organic erectile dysfunction; a Phase IIa trial for the treatment of vulvodynia; and preclinical development for the treatment of female sexual dysfunction (FSD). It is also developing IP2018, a m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK

Analyst Summary

The average 12-month stock price target for INIT is kr 5.52, which is an increase of 204.97% from the latest price.

Price Target

kr 5.52

(204.97% upside)

Data Sources: S&P Global Market Intelligence and QUODD

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by QUODD.

Last checked:

Nov 2, 2026

Data Sources Report a data error